AMP applauds US Senator Rand Paul (R-KY) for introducing new legislation to allow molecular pathology professionals to continue advancing and offering laboratory developed testing procedures (LDPs) for patient care. The Verified Innovative Testing in American Laboratories (VITAL) Act of 2020
clarifies the federal regulatory authority over LDPs and encourages the modernization of the existing Clinical
Laboratory Improvement Amendments (CLIA), which are administered by the Centers for Medicare and
Medicaid Services(CMS). The legislation was designed to enhance transparency, preserve innovation and ensure widespread patient access to essential medical services.
↧